ID

42817

Description

Ropinirole Case Report Form GSK RRL100013 GSK Study ID: 100013 Clinical Study ID: RRL100013 A 12-Week, Double-Blind, Placebo-Controlled, Twice-Daily Dosing Study to Assess the Efficacy and Safety of Ropinirole in Patients Suffering from Restless Legs Syndrome (RLS) Requiring Extended Treatment Coverage

Keywords

  1. 2/22/18 2/22/18 -
  2. 2/24/18 2/24/18 -
  3. 2/25/18 2/25/18 -
  4. 9/17/21 9/17/21 -
Copyright Holder

gsk

Uploaded on

September 17, 2021

DOI

To request one please log in.

License

Creative Commons BY-NC 3.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Ropinirole Case Report Form GSK RRL100013

Serious Adverse Event (SAE)

Serious Adverse Event (SAE) Section 1
Description

Serious Adverse Event (SAE) Section 1

Event
Description

Diagnosis Only

Data type

text

Alias
UMLS CUI [1]
C1519255
Start date
Description

Start date

Data type

date

Measurement units
  • Day Month Year
Alias
UMLS CUI [1]
C2697888
Day Month Year
Start time
Description

Start time

Data type

time

Alias
UMLS CUI [1]
C1301880
Outcome
Description

Outcome

Data type

integer

Alias
UMLS CUI [1]
C1705586
End date
Description

End date

Data type

date

Measurement units
  • Day Month Year
Alias
UMLS CUI [1]
C0806020
Day Month Year
End time
Description

End time

Data type

time

Alias
UMLS CUI [1]
C1522314
Maximum intensity
Description

Maximum intensity

Data type

text

Alias
UMLS CUI [1]
C1710066
Action Taken with lnvestigational Product
Description

Action Taken with lnvestigational Product

Data type

integer

Alias
UMLS CUI [1]
C1704758
Did the subject withdraw from study as a result of this SAE?
Description

Withdrawl

Data type

boolean

Alias
UMLS CUI [1]
C0422727
Is there a reasonable possibility the SAE may have been caused by the investigational product?
Description

Relationship to Investigational product

Data type

boolean

Alias
UMLS CUI [1,1]
C0304229
UMLS CUI [1,2]
C0085978
UMLS CUI [1,3]
C1519255
SECTION 2 Seriousness
Description

SECTION 2 Seriousness

Seriousness SAE
Description

Seriousness (specify reason(s) for considering this a SAE, ttl all that apply

Data type

integer

Alias
UMLS CUI [1]
C1710056
SECTION 3 Demography Data
Description

SECTION 3 Demography Data

Demography Data
Description

Demography Data

Data type

integer

Alias
UMLS CUI [1]
C0011298
Date of birth
Description

Date of birth

Data type

date

Measurement units
  • Day Month Year
Alias
UMLS CUI [1]
C0421451
Day Month Year
Sex
Description

Sex

Data type

integer

Alias
UMLS CUI [1]
C0079399
SECTION 4
Description

SECTION 4

Investigational Product
Description

If lnvestigational Product(s) was Stopped

Data type

integer

Alias
UMLS CUI [1,1]
C1519255
UMLS CUI [1,2]
C0304229
SECTION 5
Description

SECTION 5

Possible Causes of SAE
Description

Possible Causes of SAE

Data type

integer

Alias
UMLS CUI [1,1]
C3828190
UMLS CUI [1,2]
C1519255
SECTION 6
Description

SECTION 6

Medical Conditions
Description

RELEVANT Medical Conditions

Data type

integer

Alias
UMLS CUI [1]
C0012634
Specify any RELEVANT past or current medical disorders, allergies, surgeries, etc. that can help explain the SAE
Description

Medical history

Data type

text

Alias
UMLS CUI [1]
C0262926
Date of Onset
Description

Date of Onset

Data type

date

Alias
UMLS CUI [1]
C0574845
Condition Present at Time of the SAE?
Description

Condition Present at Time of the SAE?

Data type

boolean

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C1519255
If No, Date of Last Occurrence
Description

If No, Date of Last Occurrence

Data type

date

Alias
UMLS CUI [1,1]
C2745955
UMLS CUI [1,2]
C0011008
SECTION 7
Description

SECTION 7

Other RELEVANT Risk Factors
Description

provide any family or social history (e.g., smoking, alcohol, diet, drug abuse, occupational hazard) relevant to the SAE)

Data type

text

Alias
UMLS CUI [1]
C0035648
SECTION 8 RELEVANT Concomitant Medications
Description

SECTION 8 RELEVANT Concomitant Medications

Alias
UMLS CUI-1
C1828479
UMLS CUI-2
C2347852
Drug Name
Description

Drug Name

Data type

text

Alias
UMLS CUI [1]
C0013227
Dose
Description

Dose

Data type

integer

Alias
UMLS CUI [1]
C3174092
Unit
Description

Unit

Data type

text

Alias
UMLS CUI [1]
C1519795
Frequency
Description

Frequency

Data type

text

Alias
UMLS CUI [1]
C3476109
Route
Description

Route

Data type

text

Alias
UMLS CUI [1]
C0013153
Taken Prior to Study?
Description

Taken Prior to Study?

Data type

boolean

Alias
UMLS CUI [1]
C2826667
Start Date
Description

Start Date

Data type

date

Alias
UMLS CUI [1]
C0808070
Stop Date
Description

Stop Date

Data type

date

Alias
UMLS CUI [1]
C0806020
Ongoing Medication?
Description

Ongoing Medication?

Data type

boolean

Alias
UMLS CUI [1]
C2826666
Reason for Medication
Description

Reason for Medication

Data type

text

Alias
UMLS CUI [1,1]
C0392360
UMLS CUI [1,2]
C0013227
SECTION 9: Drug Details
Description

SECTION 9: Drug Details

Alias
UMLS CUI-1
C0013227
UMLS CUI-2
C1522508
Start Date Investigational Product (from REDUCE study)
Description

Start Date Investigational Product

Data type

date

Alias
UMLS CUI [1,1]
C0808070
UMLS CUI [1,2]
C0013230
Stop Date Investigational Product (from REDUCE study)
Description

Stop Date Investigational Product

Data type

date

Alias
UMLS CUI [1,1]
C0806020
UMLS CUI [1,2]
C0013230
Start Date Prescription Dutasteride
Description

Start Date

Data type

date

Alias
UMLS CUI [1]
C0808070
Stop Date Prescription Dutasteride
Description

Stop Date

Data type

date

Alias
UMLS CUI [1]
C0806020
SECTION 10: Details of RELEVANT Assessments
Description

SECTION 10: Details of RELEVANT Assessments

Alias
UMLS CUI-1
C0220825
Details of Relevant Assessments
Description

Provide details of any other tests/procedures which were carried out to diagnose or confirm the SAE e.g., laboratory data with units and normal range.

Data type

text

Alias
UMLS CUI [1,1]
C1261322
UMLS CUI [1,2]
C1519255
SECTION 11: Narrative Remarks
Description

SECTION 11: Narrative Remarks

Investigator's signature
Description

Investigator's signature

Data type

text

Alias
UMLS CUI [1]
C2346576
Investigator's name
Description

Investigator's name

Data type

text

Alias
UMLS CUI [1]
C2826892
Date
Description

Date

Data type

date

Alias
UMLS CUI [1]
C0011008
Narrative Remarks
Description

Provide a brief narrative description of the SAE and details of treatment given.

Data type

text

Similar models

Serious Adverse Event (SAE)

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
Serious Adverse Event (SAE) Section 1
Event
Item
Event
text
C1519255 (UMLS CUI [1])
Start date
Item
Start date
date
C2697888 (UMLS CUI [1])
Start time
Item
Start time
time
C1301880 (UMLS CUI [1])
Item
Outcome
integer
C1705586 (UMLS CUI [1])
Code List
Outcome
CL Item
Recovered (1)
C2826210 (UMLS CUI-1)
(Comment:en)
CL Item
Recovering (2)
C1709864 (UMLS CUI-1)
(Comment:en)
CL Item
Not resolved (3)
C1709277 (UMLS CUI-1)
(Comment:en)
CL Item
Resolved with sequelae (4)
C1709862 (UMLS CUI-1)
(Comment:en)
CL Item
Fatal (5)
C1302234 (UMLS CUI-1)
(Comment:en)
End date
Item
End date
date
C0806020 (UMLS CUI [1])
End time
Item
End time
time
C1522314 (UMLS CUI [1])
Maximum intensity
Item
Maximum intensity
text
C1710066 (UMLS CUI [1])
Item
Action Taken with lnvestigational Product
integer
C1704758 (UMLS CUI [1])
Code List
Action Taken with lnvestigational Product
CL Item
lnvestigational withdrawn (1)
C2349954 (UMLS CUI-1)
C0008976 (UMLS CUI-2)
(Comment:en)
CL Item
dose reduced (2)
C1707814 (UMLS CUI-1)
(Comment:en)
CL Item
dose increased (3)
C1707810 (UMLS CUI-1)
(Comment:en)
CL Item
dose not changed (4)
C0178602 (UMLS CUI-1)
C0443172 (UMLS CUI-2)
(Comment:en)
CL Item
dose interrupted (5)
C1512900 (UMLS CUI-1)
C0178602 (UMLS CUI-2)
(Comment:en)
CL Item
not applicable (6)
C1272460 (UMLS CUI-1)
(Comment:en)
Withdrawl
Item
Did the subject withdraw from study as a result of this SAE?
boolean
C0422727 (UMLS CUI [1])
Relationship to Investigational product
Item
Is there a reasonable possibility the SAE may have been caused by the investigational product?
boolean
C0304229 (UMLS CUI [1,1])
C0085978 (UMLS CUI [1,2])
C1519255 (UMLS CUI [1,3])
Item Group
SECTION 2 Seriousness
Item
Seriousness SAE
integer
C1710056 (UMLS CUI [1])
Code List
Seriousness SAE
CL Item
Results in death (1)
C1320832 (UMLS CUI-1)
(Comment:en)
CL Item
Results in disability/incapacity (2)
C0231170 (UMLS CUI-1)
(Comment:en)
CL Item
Is life-threatening (3)
C1517874 (UMLS CUI-1)
(Comment:en)
CL Item
Requires hospitalisation or prolongation of Congenital anomaly/birth defect (4)
C0019993 (UMLS CUI-1)
(Comment:en)
CL Item
 (5)
(Comment:en)
CL Item
Other, specify _______________________existing hospitalisation (see definition) (6)
C0522473 (UMLS CUI-1)
C3840932 (UMLS CUI-2)
(Comment:en)
CL Item
 (7)
(Comment:en)
Item Group
SECTION 3 Demography Data
Demography Data
Item
Demography Data
integer
C0011298 (UMLS CUI [1])
Date of birth
Item
Date of birth
date
C0421451 (UMLS CUI [1])
Item
Sex
integer
C0079399 (UMLS CUI [1])
Code List
Sex
CL Item
Male (1)
CL Item
Female (2)
Item Group
SECTION 4
Item
Investigational Product
integer
C1519255 (UMLS CUI [1,1])
C0304229 (UMLS CUI [1,2])
Code List
Investigational Product
CL Item
Yes (1)
CL Item
No (2)
CL Item
Unknown at this time (3)
Item Group
SECTION 5
Item
Possible Causes of SAE
integer
C3828190 (UMLS CUI [1,1])
C1519255 (UMLS CUI [1,2])
Code List
Possible Causes of SAE
CL Item
Disease under study (1)
C0012634 (UMLS CUI-1)
(Comment:en)
CL Item
Concomitant medication (2)
C2347852 (UMLS CUI-1)
(Comment:en)
CL Item
Medical condition (3)
C1699700 (UMLS CUI-1)
(Comment:en)
CL Item
Activity related to study participation (e.g., procedures) (4)
C2348568 (UMLS CUI-1)
(Comment:en)
CL Item
Lack of efficacy (5)
C0235828 (UMLS CUI-1)
(Comment:en)
CL Item
Other, specify ______________________ (6)
C2911685 (UMLS CUI-1)
C1521902 (UMLS CUI-2)
(Comment:en)
CL Item
Withdrawal of investigational product(s) (7)
C2349954 (UMLS CUI-1)
C0013227 (UMLS CUI-2)
(Comment:en)
Item Group
SECTION 6
RELEVANT Medical Conditions
Item
Medical Conditions
integer
C0012634 (UMLS CUI [1])
Medical history
Item
Specify any RELEVANT past or current medical disorders, allergies, surgeries, etc. that can help explain the SAE
text
C0262926 (UMLS CUI [1])
Date of Onset
Item
Date of Onset
date
C0574845 (UMLS CUI [1])
Condition Present at Time of the SAE?
Item
Condition Present at Time of the SAE?
boolean
C0012634 (UMLS CUI [1,1])
C1519255 (UMLS CUI [1,2])
If No, Date of Last Occurrence
Item
If No, Date of Last Occurrence
date
C2745955 (UMLS CUI [1,1])
C0011008 (UMLS CUI [1,2])
Item Group
SECTION 7
Other RELEVANT Risk Factors
Item
Other RELEVANT Risk Factors
text
C0035648 (UMLS CUI [1])
Item Group
SECTION 8 RELEVANT Concomitant Medications
C1828479 (UMLS CUI-1)
C2347852 (UMLS CUI-2)
Drug Name
Item
Drug Name
text
C0013227 (UMLS CUI [1])
Dose
Item
Dose
integer
C3174092 (UMLS CUI [1])
Unit
Item
Unit
text
C1519795 (UMLS CUI [1])
Frequency
Item
Frequency
text
C3476109 (UMLS CUI [1])
Route
Item
Route
text
C0013153 (UMLS CUI [1])
Taken Prior to Study?
Item
Taken Prior to Study?
boolean
C2826667 (UMLS CUI [1])
Start Date
Item
Start Date
date
C0808070 (UMLS CUI [1])
Stop Date
Item
Stop Date
date
C0806020 (UMLS CUI [1])
Ongoing Medication?
Item
Ongoing Medication?
boolean
C2826666 (UMLS CUI [1])
Reason for Medication
Item
Reason for Medication
text
C0392360 (UMLS CUI [1,1])
C0013227 (UMLS CUI [1,2])
Item Group
SECTION 9: Drug Details
C0013227 (UMLS CUI-1)
C1522508 (UMLS CUI-2)
Start Date Investigational Product
Item
Start Date Investigational Product (from REDUCE study)
date
C0808070 (UMLS CUI [1,1])
C0013230 (UMLS CUI [1,2])
Stop Date Investigational Product
Item
Stop Date Investigational Product (from REDUCE study)
date
C0806020 (UMLS CUI [1,1])
C0013230 (UMLS CUI [1,2])
Start Date
Item
Start Date Prescription Dutasteride
date
C0808070 (UMLS CUI [1])
Stop Date
Item
Stop Date Prescription Dutasteride
date
C0806020 (UMLS CUI [1])
Item Group
SECTION 10: Details of RELEVANT Assessments
C0220825 (UMLS CUI-1)
Details of Relevant Assessments
Item
Details of Relevant Assessments
text
C1261322 (UMLS CUI [1,1])
C1519255 (UMLS CUI [1,2])
Item Group
SECTION 11: Narrative Remarks
Investigator's signature
Item
Investigator's signature
text
C2346576 (UMLS CUI [1])
Investigator's name
Item
Investigator's name
text
C2826892 (UMLS CUI [1])
Date
Item
Date
date
C0011008 (UMLS CUI [1])
Narrative Remarks
Item
Narrative Remarks
text

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial